GlassScriptPhysician profile
Amy S Carter
NPI 1124121629
$48,885.35
in general payments reported to CMS, 2019-2025
26 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $527 · 2021: $46K · 2022: $616 · 2023: $574 · 2024: $208 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.41 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46,487.20 | 2019-2022 | |
| Abbvie INC. | $797.33 | 2019-2025 | Botox, Liletta, Lo Loestrin Fe |
| Galderma Laboratories, L.P. | $499.63 | 2019-2025 | Dysport |
| Astellas Pharma US INC | $164.13 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $136.13 | 2021-2024 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Merz North America, INC. | $100.00 | 2019 | |
| Daiichi Sankyo INC. | $96.68 | 2020-2021 | |
| Channel Medsystems, INC. | $70.07 | 2023 | |
| Avion Pharmaceuticals | $64.28 | 2020-2021 | |
| Exeltis, USA INC. | $55.99 | 2019-2022 | |
| Organon LLC | $51.33 | 2022-2024 | Nexplanon |
| Therapeuticsmd, INC. | $47.55 | 2020-2022 | |
| Coopersurgical, INC. | $43.25 | 2019-2021 | |
| Medtronic, INC. | $38.31 | 2021 | |
| Amgen INC. | $31.40 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $30.43 | 2019-2020 | |
| Evofem Biosciences, INC. | $30.06 | 2021 | |
| Biogen, INC. | $20.83 | 2024 | |
| Pfizer INC. | $17.38 | 2023 | |
| Merck Sharp & Dohme LLC | $16.74 | 2024 | Gardasil 9, Gardasil |
| Pacira Pharmaceuticals Incorporated | $16.31 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.57 | 2019 | |
| Sumitomo Pharma America, INC. | $14.19 | 2023 | Myfembree |
| Minerva Surgical, INC | $14.02 | 2019 | |
| Currax Pharmaceuticals LLC | $13.79 | 2022 | |
| Myovant Sciences INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.